Jung-Mo Ahn

This inventor holds 14 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 1 EPO patent, primarily in Cancer Treatment. Top assignee: The University of Texas System. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jung-Mo Ahn. Retrieved from https://idiyas.com/inventor/jung-mo-ahn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 7)

% Patents Active = 85.7

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 1.6

ph-index = 4

Forward Citations = 36(Granted Patents)

Location History:

Richardson, TX (US) (2010 - 2016)
Plano, TX (US) (2014 - 2020)

Company Filing History:

14 out of 5,645

The University of Texas System

patents

Years Active: 2010-2025

Loading Chart...

Areas of Expertise:

Histone Demethylase Inhibitors

Oligo-Benzamide Compounds

Cancer Treatment

Cyclic Peptide Analogues

Non-Invasive Imaging

Apoptosis

Histone Deacetylase Inhibitors

Peptide Receptor

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12378201 - Histone demethylase inhibitors for treating cancers (2025-08-05),

2. 12275685 - Oligo-benzamide analogs and their use in cancer treatment (2025-04-14),

3. 10618869 - Oligo-benzamide compounds and their use (2020-04-14),

4. 9856206 - Oligo-benzamide compounds and their use (2018-01-02),

5. 9458095 - Oligo-benzamide compounds and their use in treating cancers (2016-10-04),

6. 9394241 - Composition and method for making oligo-benzamide compounds (2016-07-19),

7. 9072705 - Oligo-benzamide compounds and their use in treating cancers (2015-07-07),

8. 8992886 - Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells (2015-03-31),

9. 8835493 - Oligo-benzamide compounds for use in treating cancers (2014-09-16),

10. 8754124 - Oligo-benzamide compounds and their use in treating cancers (2014-06-17),

11. 8618324 - Composition and method for making oligo-benzamide compounds (2013-12-31),

12. 8236983 - Composition and method for the treatment of diseases affected by apoptosis (2012-08-07),

13. 8034768 - Composition and method for the treatment of diseases affected by histone deacetylase inhibitors (2011-10-11),

14. 7816324 - Composition and method for the treatment of diseases affected by a peptide receptor (2010-10-19),

Title: Innovations in Cancer Treatment by Jung-Mo Ahn

Introduction

Jung-Mo Ahn is a prominent inventor based in Plano, TX (US), known for his significant contributions to cancer treatment through innovative pharmaceutical research. With a total of 14 patents, Ahn has developed groundbreaking compounds that target specific enzymes involved in cancer progression.

Latest Patents

Among his latest patents, Ahn has introduced histone demethylase inhibitors for treating cancers. This patent discloses a new series of 8-hydroxyquinoline derivatives that serve as potent KDM4 inhibitors, demonstrating high activity and selectivity against KDM4 enzymes. Additionally, the patent outlines pharmaceutical compositions that include these inhibitors, along with methods for their use in treating cancer and neoplastic diseases. Another notable patent involves oligo-benzamide analogs, which are also aimed at cancer treatment. This disclosure includes compounds with defined formulae and pharmaceutical compositions, as well as methods for their application in cancer therapy.

Career Highlights

Jung-Mo Ahn is affiliated with the University of Texas System, where he conducts his research and development work. His innovative approach to cancer treatment has positioned him as a key figure in the field of pharmaceutical sciences.

Collaborations

Ahn collaborates with esteemed colleagues such as Ganesh Raj and Ratna K Vadlamudi, contributing to a dynamic research environment focused on advancing cancer therapies.

Conclusion

Jung-Mo Ahn's work exemplifies the intersection of innovation and healthcare, particularly in the realm of cancer treatment. His patents reflect a commitment to developing effective therapeutic options for patients battling cancer.

Profile summary based on public USPTO records.